


Product data sheet



MedKoo Cat#: 585073 Name: JTP 103237 CAS: 1883864-16-1 Chemical Formula: C ₂₄ H ₂₉ F ₃ N ₆ O Exact Mass: 474.2355 Molecular Weight: 474.5322	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

JTP 103237 is a potent and selective monoacylglycerol acyltransferase 2 (MOGAT2) inhibitor.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	9.49	20.0
Ethanol	47.45	100.0

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.11 mL	10.54 mL	21.07 mL
5 mM	0.42 mL	2.11 mL	4.21 mL
10 mM	0.21 mL	1.05 mL	2.11 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

TBD

In vivo study

1. Okuma C, Ohta T, Tadaki H, Ishigure T, Sakata S, Taniuchi H, Sano R, Hamada H, Kume S, Nishiu J, Kakutani M. JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. *J Pharmacol Sci.* 2015 Jul;128(3):150-7. doi: 10.1016/j.jphs.2015.06.007. Epub 2015 Jul 2. PMID: 26215699.

7. Bioactivity

Biological target:

Potent and selective monoacylglycerol acyltransferase 2 (MOGAT2) inhibitor.

In vitro activity

TBD

In vivo activity

In the present study, JTP-103237 prevented carbohydrate-induced fatty liver and suppressed both TG synthesis and de novo lipogenesis, suggesting MGAT inhibitor may prevent carbohydrate-induced metabolic disorders, including NAFLD, obesity and

Product data sheet



diabetes. The results showed that JTP-103237 significantly decreased hepatic triglyceride (45.0 ± 5.5 mg/g liver in vehicle group and 27.1 ± 7.3 mg/g liver, respectively. $P < 0.01$ in Student's t-test) in mice.

Reference: J Pharmacol Sci. 2015 Jul;128(3):150-7. <https://pubmed.ncbi.nlm.nih.gov/26215699/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.